For US residents only.

Treatment Information


Adjuvant treatment for BRAF+ melanoma after surgery

TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) is the first combination therapy that can be used as an adjuvant treatment for BRAF-positive (also written as BRAF+) melanoma after surgery. TAFINLAR + MEKINIST works for patients whose melanoma has a certain type of abnormal BRAF (V600E or V600K mutation-positive) gene as determined by an FDA-approved test.

Man on fishing trip

What is adjuvant treatment?

Adjuvant treatment is additional therapy given after a primary treatment in order to further decrease the risk that the cancer will progress. In this case, your health care provider will prescribe you TAFINLAR + MEKINIST as adjuvant therapy after you've undergone complete resection of BRAF+ stage III melanoma.

What is BRAF+ melanoma?

Sometimes changes occur within the DNA of your cells. These genetic changes are referred to as mutations. The type of advanced melanoma you have can be based on the presence or absence of genetic changes within the melanoma cells. If you have BRAF+ melanoma, the cells in your tumors have mutations in the BRAF gene. This causes the cells to grow and spread out of control. Your doctor will give you an FDA-approved test to see if your melanoma contains these mutations.


Patients with BRAF mutations have the option of taking targeted therapies, such as BRAF and MEK inhibitors, which are designed to target cells with a BRAF gene mutation and treat this form of advanced melanoma. These targeted therapies are intended to work by blocking the action of certain proteins associated with the BRAF gene so that they inhibit the faulty signals that can lead to the growing and spreading of cancer cells such as melanoma. Targeted therapy can also affect healthy cells.

TAFINLAR + MEKINIST combination therapy targets 2 different points in a pathway that sends signals in cells. Although TAFINLAR + MEKINIST combination therapy has been studied in patients who have advanced melanoma with a mutated BRAF gene, the way that TAFINLAR + MEKINIST combination therapy works has only been shown in laboratory studies. Medical research has shown that TAFINLAR + MEKINIST combination therapy may slow the growth of certain melanoma cancer cells that have an abnormal BRAF gene.


The recommended daily dose is TAFINLAR 150 mg twice daily plus MEKINIST 2 mg once daily. You will take TAFINLAR + MEKINIST by mouth. Take your medication at least 1 hour before or at least 2 hours after eating.


Daily dosing for TAFINLAR + MEKINIST


Important dosing information

  • Do not open, crush, or break TAFINLAR capsules
  • If you miss a dose of TAFINLAR or MEKINIST, take it as soon as you remember, unless:

    – You've missed TAFINLAR and it is within 6 hours of your next scheduled dose, or

    – You've missed MEKINIST and it is within 12 hours of your next scheduled dose
    In either case, just take your next dose at the regular time. Do not make up for the missed dose.

It is important that you understand and follow your doctor's directions for taking TAFINLAR + MEKINIST. Do not change your dose, or stop TAFINLAR or MEKINIST, unless your doctor tells you to.

What are possible side effects of TAFINLAR + MEKINIST?

As with many medications, you may experience side effects while taking TAFINLAR + MEKINIST. Talk to your health care provider right away if you experience any side effects. Your doctor may choose to modify, interrupt, or discontinue your dosage.

Some common side effects of TAFINLAR + MEKINIST:

Fever graphic


Fatigue graphic


Nausea graphic


Headache graphic


Diarrhea graphic


For more information about what to expect on your TAFINLAR + MEKINIST treatment journey, download the patient brochure below.